SCRN1 is a novel marker for prognosis in colorectal cancer

Norikatsu Miyoshi, Hideshi Ishii, Koshi Mimori, Mitsugu Sekimoto, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. Materials and Methods: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC.We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. Results: Thirty of the 54 (55.5%) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. Conclusion: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.

Original languageEnglish
Pages (from-to)156-159
Number of pages4
JournalJournal of Surgical Oncology
Volume101
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Colorectal Neoplasms
Cell Line
Neoplasm Antigens
Immunotherapy
Small Interfering RNA
Disease-Free Survival
Stomach Neoplasms
Gene Expression
Growth
Genes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

SCRN1 is a novel marker for prognosis in colorectal cancer. / Miyoshi, Norikatsu; Ishii, Hideshi; Mimori, Koshi; Sekimoto, Mitsugu; Doki, Yuichiro; Mori, Masaki.

In: Journal of Surgical Oncology, Vol. 101, No. 2, 01.02.2010, p. 156-159.

Research output: Contribution to journalArticle

Miyoshi, Norikatsu ; Ishii, Hideshi ; Mimori, Koshi ; Sekimoto, Mitsugu ; Doki, Yuichiro ; Mori, Masaki. / SCRN1 is a novel marker for prognosis in colorectal cancer. In: Journal of Surgical Oncology. 2010 ; Vol. 101, No. 2. pp. 156-159.
@article{440f62574a0f4e1db899975df99e390c,
title = "SCRN1 is a novel marker for prognosis in colorectal cancer",
abstract = "Purpose: Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. Materials and Methods: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC.We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. Results: Thirty of the 54 (55.5{\%}) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. Conclusion: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.",
author = "Norikatsu Miyoshi and Hideshi Ishii and Koshi Mimori and Mitsugu Sekimoto and Yuichiro Doki and Masaki Mori",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/jso.21459",
language = "English",
volume = "101",
pages = "156--159",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - SCRN1 is a novel marker for prognosis in colorectal cancer

AU - Miyoshi, Norikatsu

AU - Ishii, Hideshi

AU - Mimori, Koshi

AU - Sekimoto, Mitsugu

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Purpose: Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. Materials and Methods: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC.We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. Results: Thirty of the 54 (55.5%) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. Conclusion: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.

AB - Purpose: Secernin 1 (SCRN1) is a member of the secernin family and is reported to be a tumor-associated antigen. Previous reports show that SCRN1 is upregulated in gastric cancer cell lines and may be a novel immunotherapy target, whereas its significance in colorectal cancer (CRC) is not fully understood. Materials and Methods: The present study comprised 54 patients who underwent surgery for CRC, as well as two cell lines derived from human CRC.We assessed the correlation of gene expression with clinical parameters in the CRC patients, and knockdown was evaluated in the cell lines. Results: Thirty of the 54 (55.5%) cases exhibited a higher expression of the SCRN1 gene in cancerous regions than marginal non-cancerous regions. Patients with high SCRN1 expression were statistically susceptible to a poor prognosis and showed poorer disease-free survival than those with low expression. SCRN1 knockdown in the two cell lines demonstrated that the siRNA inhibition resulted in a statistically significant reduction in cell growth. Conclusion: The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=76549095030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549095030&partnerID=8YFLogxK

U2 - 10.1002/jso.21459

DO - 10.1002/jso.21459

M3 - Article

VL - 101

SP - 156

EP - 159

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -